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Abstract
Background: Facioscapulohumeral muscular dystrophy (FSHD; OMIM 158900 & 158901) is a progressive skeletal
muscle dystrophy, characterized by an autosomal dominant inheritance pattern. One of the major unsolved
questions in FSHD is the marked clinical heterogeneity, ranging from asymptomatic individuals to severely affected
patients with an early onset. An estimated 10 % of FSHD patients have an early onset (onset before 10 years of
age) and are traditionally classified as infantile FSHD. This subgroup is regarded as severely affected and extra-
muscular symptoms, such as hearing loss and retinopathy, are frequently described. However, information on the
prevalence, natural history and clinical management of early onset FSHD is currently lacking, thereby hampering
adequate patient counselling and management. Therefore, a population-based prospective cohort study on FSHD
in children is highly needed.
Methods/design: This explorative study aims to recruit all children (aged 0–17 years) with a genetically confirmed
diagnosis of FSHD in The Netherlands. The children will be assessed at baseline and at 2-year follow-up. The
general aim of the study is the description of the clinical features and genetic characteristics of this paediatric
cohort. The primary outcome is the motor function as measured by the Motor Function Measure. Secondary
outcomes include quantitative and qualitative description of the clinical phenotype, muscle imaging, genotyping
and prevalence estimations. The ultimate objective will be a thorough description of the natural history, predictors
of disease severity and quality of life in children with FSHD.
Discussion: The results of this population-based study are vital for adequate patient management and clinical
trial-readiness. Furthermore, this study is expected to provide additional insight in the epigenetic and
environmental disease modifying factors. In addition to improve counselling, this could contribute to
unravelling the aetiology of FSHD.
Trial registration: clinicaltrials.gov NCT02625662.
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Background
Facioscapulohumeral dystrophy (FSHD) is a muscular
dystrophy characterized by progressive weakness and at-
rophy of the facial (facio-), shoulder-upper arm (scapulo-
humeral-), axial- and leg muscles [1–3]. FSHD is one of
the most prevalent muscular dystrophies with an esti-
mated prevalence of 12:100.000 [4].
One of the hallmarks of FSHD is its clinical hetero-
geneity; the spectrum varies from severely affected,
wheelchair bound children to asymptomatic carriers in
late adulthood, even within families with the same
repeat contraction [1, 5, 6]. Typically FSHD has an
onset in adolescence and life expectancy is not im-
paired [7]. However, a subgroup of patients has a child-
hood onset and is associated with more severe disease
progression. FSHD is increasingly recognized as an epi-
genetic disease, which could be an explanation for this
clinical heterogeneity.
Classification
Traditionally, children with very early onset have been
classified as a distinct disease identity named infantile
FSHD [8], based on the following criteria [9]:
– signs or symptoms of facial weakness before the age
of 5 and
– signs or symptoms of scapular weakness before the
age of 10
The concept of two FSHD types has gradually devel-
oped to an FSHD spectrum, with infantile onset being
on the severe end and asymptomatic carriers on the
other end. Accordingly, recent articles mostly classify
the disease severity according to the repeat length of
the genetic defect in FSHD1 [10–12]. However, the cor-
relation between disease severity and repeat length is
inconsistent and is influenced by other genetic and
environmental modifiers [13–15]. A generally accepted
definition of severely affected FSHD or early onset
“classical” patients is currently lacking.
Prevalence
Few studies have investigated the prevalence of child-
hood onset FSHD and these studies have used different
selection criteria. Estimations of early onset FSHD vary
between 3–21 % of the total FSHD population [1, 16]
and 58 % of the pediatric FSHD population (onset at any
age < 18 years [17]). Accurate prevalence estimations of
childhood onset FSHD are useful for interpretation of
clinical studies, planning and increasing clinical trial-
readiness.
Extramuscular symptoms
Various extramuscular symptoms such as epilepsy, hear-
ing difficulties, retinal abnormalities (Coats’ syndrome),
mental retardation and cardiac arrhythmias are associated
with FSHD and they are most frequently described in the
early onset subgroup [9–12, 17–19]. Little is known
regarding the prevalence and aetiology of these extramus-
cular symptoms in children with FSHD. The current body
of knowledge may be skewed by publication bias, selection
bias and no/incorrect molecular diagnoses.
Genetics
FSHD is increasingly recognized as an epigenetic dis-
ease. The most frequent cause of FSHD is contraction
of the polymorphic D4Z4 macrosatellite repeat array in
the subtelomere of chromosome 4 at 4q35 resulting in
FSHD type 1 (FSHD1) [20]. This mutation explains >95 %
of the adult cases and all known infantile cases. Healthy
individuals have 8 or more D4Z4 repeats on each 4q35
copy, whereas patients with FSHD1 have 1–10 repeats on
one copy of the 4q35 chromosome region and a disease-
permissive allele 4A on the chromosome 4q subtelomere.
In contrast to 4A alleles, 4B alleles, which lack a polya-
denlylation signal for the DUX4 gene which is embed-
ded in each repeat of the D4Z4 array, are non-permissive
to the disease [21]. There is a copy of the D4Z4 repeat
array on chromosome 10, but in absence of a DUX4 poly-
adenylation signal, contractions of this array are also not
pathogenic [22].
This causative genotype explains the variability in dis-
ease onset and progression only to some extent. The
inverse correlation between residual repeat length and
disease severity (short repeat lengths are associated with
an earlier onset, wheelchair dependency and extramus-
cular involvement [23, 24]) is imperfect; for example, it
does not explain the intra-familial differences in pheno-
type. Aberrant epigenetic regulation of the D4Z4 chro-
matin structure is thought to play an important role in
this clinical heterogeneity, and disruption of the 4q35
D4Z4 array chromatin structure in somatic cells is
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associated with all forms of FSHD [25, 26]. These epi-
genetic disruptions can be environmentally influenced
and are important therapeutic targets. Epigenetic disrup-
tions in FSHD include chromatin relaxation through the
SMCHD1 or DNMT3B gene defect causing FSHD type
2 (FSHD2) [13, 27], hypomethylation [14], alternative
RNA splicing and nucleosome remodelling [15]. Investi-
gating novel (epi)genetic characteristics in children with
FSHD and linking this genetic profile to disease severity
and age at onset will contribute to better predictors of
prognosis and understanding of the pathogenesis.
Clinical management
A highly needed evidence-based guideline for the diagno-
sis and management of FSHD has recently been published
[28]. However, a specific guideline for children with FSHD
and adult patients with early onset FSHD is currently lack-
ing. Furthermore, adequate information on natural history
and disease markers are important for clinical trial-
preparedness [29], with fast approaching therapeutic trials
[30–32].
In conclusion, data on the natural history, predictors
and optimal clinical management of children with FSHD
is limited. Thorough description of the clinical and gen-
etic characteristics is vital for adequate management and
could help to elucidate the underlying aetiology [31, 33].
Here we describe the objectives and methods of this
population-based, prospective, observational study on
early onset FSHD.
Objectives
The primary objective of the study is:
1. to assess the clinical, genetic and epigenetic features
of children with FSHD to optimize clinical
management.
The secondary objectives are:
2. to define a new comprehensive definition of early
onset FSHD;
3. to provide prevalence estimations of early onset
FSHD in The Netherlands;
4. to establish a well-characterized baseline cohort for
prospective follow-up and recruitment for future
clinical trials;
5. to assess 2-year disease progression rate in children
with FSHD and develop a prognostic model.
Methods and design
Project design
The iFocus study is a prospective observational study per-
formed at the department of paediatric Neurology of the
Radboud University Medical Center, The Netherlands; it is
a tertiary referral center for neuromuscular diseases.
Genetic and epigenetic studies will be performed in the
department of Human Genetics of the Leiden University
Medical Center, The Netherlands. Participation in the
study will not affect the usual care provided by the pa-
tients’ own medical team.
Study population
Eligible patients are children aged 0–17 years with symp-
toms of facioscapulohumeral dystrophy and genetically
proven FSHD1 or FSHD2 living in The Netherlands.
Exclusion criteria are: inability or unwillingness to provide
informed consent. The aim is to include all children in
The Netherlands with a genetically confirmed diagnosis of
FSHD. We expect to include 20–30 patients based on the
estimated prevalence in the population [4].
There is no agreement on the classification of chil-
dren with FSHD. Therefore we chose to include all
patients less than 18 years with genetically confirmed
FSHD, including for example children with isolated
hearing loss as well. This enables us to describe the
complete spectrum of children with FSHD. In addition,
this study could identify predictors of severity and
prognosis, thereby serving as a reference for working
towards a widely accepted classification.
Recruitment and screening
Participants will be recruited non-selectively and con-
secutively in the period from November 2015-November
2016. In order to estimate the prevalence of FSHD in
children, we will try to reach all children with FSHD in
The Netherlands through a very intensive recruitment.
All Dutch paediatric neurologists, paediatricians and
specialized paediatric physiotherapists will be person-
ally asked about potential participants. In addition, all
patients registered at the Dutch neuromuscular patient
association [34] and the databases CRAMP [35] and
Focus (NL48204.091.14) will be personally informed.
Thirdly, we will directly recruit participants through
promotion of our study on patient information days,
patient websites and social media.
In order to provide data on the complete spectrum of
children with FSHD we aim to identify all children with
clinically suspected FSHD, with or without genetic con-
firmation of FSHD. For this study we defined clinically
suspected FSHD as: clinical weakness of the facial and/or
upper-arm muscles for which the patient sought medical
attention with exclusion of other diagnoses. For the chil-
dren without genetic confirmation there are two scenarios:
1. Patients with clinically suspected FSHD and an
FSHD-affected family member. Patients will be
included in the study and genetic tests will be
performed after obtaining informed consent.
2. Children with clinically suspected FSHD without an
FSHD-affected family member will be invited for a
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pre-inclusion screening. This pre-screening will
involve clinical examination by two of the authors
(CE and RG). If FSHD is clinically highly suspected,
the patient will be counselled for further assessments
(i.e. genetic testing and referral to a specialized
childhood neurologist for further rehabilitation care).
If the diagnosis is genetically confirmed, the patient
can be included in the study. If clinical suspicion is
low or the genetic testing is negative, the children
will not be included in the study and will be referred
back to their treating medical staff (Fig. 1).
Assessments
Participants will be invited for a baseline visit at the depart-
ment of paediatric neurology at the Radboud University
Medical Center. If the patient is unable to visit the hospital,
the patient is offered a home visit and auditory, ophthalmo-
logic and ultrasonography procedures will be omitted.
Patients will have a follow-up visit after 2 years.
Demographics
Date of birth, sex, weight (Kg), height (m) and medication
will be recorded. Clinical characteristics of both parents
will be directly examined and the genealogy of 3 consecu-
tive generations will be drawn. The growth curves and
medical history and medication use will be registered.
Outcome measures
The outcome measures are listed in Table 1 and are
structured according to the format of the International
Classification of Functioning, Disability and Health for
children and youth (ICF-CY [36]). The ICF is the
World Health Organization framework for measuring
health and disability at both individual and population
levels and is subdivided in body functions, body struc-
tures, activities and participation and environmental
factors. All procedures will be assessed at baseline visit
and after 2-year follow-up if not otherwise specified.
Outcome measures are listed in Table 1 and are exten-
sive due to the explorative character of the study. The
primary outcome is the motor function as measured by
the Motor Function Measure [37, 38]. This measure spe-
cifically includes axial and upper limb functions, is
designed for both ambulatory and non-ambulatory pa-
tients and can be continued into adulthood. Motor per-
formance is supplementary assessed using the 6 min
walking test, handgrip dynamometer and manual muscle
testing MRC-scores. The FSHD evaluation score and the
age-adjusted clinical severity scale are scored to explore
the validity of these scales in children. In addition, non-
muscular symptoms are extensively tested based on earl-
ier literature on childhood onset FSHD [9–11, 17–19].
Quantitative muscle ultrasonography (QMUS) will be
used to screen for muscle myopathy/inflammation. QMUS
is a patient-friendly non-invasive method to screen for
dystrophic changes in skeletal muscle [39]. The technique
has been well-validated for screening and follow-up in
several childhood and adult neuromuscular disorders [40].
The following muscles will be measured on both sides,
using a fixed scanning protocol and settings as previously
described [41, 42]: depressor anguli oris, masseter, sterno-
cleidomastoideus, biceps brachii, rectus abdominis, rectus
femoris, gastrocnemicus and tibialis anterior [43, 44].
Extramuscular symptoms will be assessed based on
symptoms as reported in literature. This will include an
extensive ophthalmologic screening, including optical
coherence tomography with angiography for specific
focus on the retinal arteries [45], a tone- and speech
audiometry, electrocardiogram (ECG) and spirometry.
Electro-encephalography (EEG) and spinal x-ray will be
performed if indicated.
Prevalence
An improvement of the prevalence estimations will be
assessed by comparing our recruitment with anonymous
data of the genetic testing by the Leiden University Medical
Center, where all Dutch samples are tested. This method is
based on earlier research in the adult population [4].
(Epi)genetic disease-modifying factors
To explore the relationship between (epi)genetic disease-
modifying factors and the disease severity, an extensive
qualitative history is taken. Focus is on medical history
Fig. 1 Flow chart of inclusion
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(traumata, infections), dietary intake and maternal and
perinatal health, including maternal substance use.
From participants and biological parents (if available)
high molecular weight DNA and RNA will be isolated
from peripheral blood mononucleated cell (PBMCs).
The sizing of the D4Z4 repeats on chromosomes 4 and
10 will be executed using pulsed field gel electrophoresis
(PFGE) and the haplotype analysis by hybridization of
PFGE blots with probes A and B in combination with
PCR-based SSLP analysis [21, 22]. Methylation of the
D4Z4 repeat will be established at the FseI restriction
site in the proximal unit of the D4Z4 array [26, 27]. In
case of reduced CpG methylation at D4Z4, gene muta-
tions in SMCHD1 or DNMT3B will be analysed by
Sanger sequencing and predicted splice site mutations or
nonsense mutations will be further analysed using cDNA
isolated from PBMCs.
For RNA isolation from PBMCs we use PAXgene
Blood RNA tubes which will be processed for obtaining
high quality RNA for whole genome RNA sequencing
analysis (RNAseq).
Cohort for future trial acquisition
An additional goal of this study is to obtain a well-
documented cohort for longer (>2 years) follow-up and
future trial acquisition. Patients will be asked to partici-
pate in the Dutch FSHD registration study [46] and for
biomaterial storage. Serum samples of the participant
and both biological parents will be stored in the Rad-
boud biobank (http://www.radboudbiobank.nl/nl/) and
are available for future DNA and/or RNA research for
researchers worldwide.
Data collection
All parents/legal guardians of participants will receive an
online form with the standardized questionnaires. All par-
ticipants > 8 years will also receive an online form with the
standardized questionnaires for children. The forms will be
sent through Castor and directly stored in the Castor data-
base (Version 2015, [47]). All data-management and data-
monitoring will be performed within the Castor software.
Statistics
The Statistical Package for the Social Sciences (SPSS
version 22, IBM, Armonk, New York) will be used to
conduct all statistical analyses. Due to the explorative
Table 1 Outcome measures and tests at baseline and follow-up
Outcome domain Tests Age
Primary outcome measure
ICF: Activities and participation
Motor function Motor Function Measure
[37, 38]
2–18
Secondary outcome measures
ICF: body functions
Mental functions Education level (school level) 5–18
EEG [48]a 0–18
Denver II developmental
screening test [49]
0–6
Seeing functions Visual acuity (Snellen) 4–18
Hearing functions Tone- and speech
audiometry
2–18
Pain Faces scale pain [50] 6–18
Cardiac function ECG [51] 0–18
Aerobic exercise tolerance 6-minute walk test
MWT [52, 53]
walk
Fatigability NeuroQol fatigue
domain [54]
2–18
Respiratory function Forced vital capacity and
forced expiratory volume
Spirometry [55]
6–18
Digestive, defecation, weight
maintenance and urination
functions
Qualitative history 0–18
Ingestion functions TOMASS-C test [56] 6–18
Neuromuscular disease
swallowing status scale [57]
2–18
Dysphagia questionnaire
[40, 58]
2–18
Muscle functions Handgrip dynamometer 6–18
Manual muscle
testing [59]
0–18
Serum creatine
kinase (CK)
0–18
Age-adjusted clinical
severity scale [60, 61]
5–18
FSHD evaluation
score [62]
ICF: Body structure
Eye structure Slit lamp examination 4–18
Dilated fundoscopy 4–18
Optical coherence
angiography tomography
6–18
Movement related structures Muscle
ultrasonography [39]
0–18
Spine x-raya 4–18
ICF: Activities and participation
Communication/social
interactions
Social Economic
Questionnaire
SEV [63]a
4–18
Table 1 Outcome measures and tests at baseline and follow-up
(Continued)
Self-care/life areas Kidscreen [64] 8–18
ICF: Environmental factors
Products and natural
environment
Qualitative anamnesis
and history
0–18
a Only if clinically indicated
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nature of the iFocus study, descriptive statistics will be
applied to describe all patient characteristics. Continu-
ous data are described as mean ± standard deviations. If
reference values are available from literature, we will
check for overlapping confidence intervals. Number of
non-missing values is described (missing data are not
replaced) unless stated otherwise. For describing the
D4Z4 CpG methylation corrected repeat size, the delta 1
score will be used [14].
Correlations between (novel) molecular markers and
clinical severity will be assessed with Spearman rank
correlation. Possible correlations will be assessed on
the following variables: ‘corrected repeat length’, ‘age at
investigation’, ‘hereditary pattern’ ‘age at onset’, various
extramuscular symptoms, FSHD severity score and
motor function measurement scores. If novel (molecu-
lar) variables are found, these will be added in the stat-
istical model. To minimize the multicolinearity manual
backward reduction will be executed.
For the clinical prediction model, multiple linear re-
gressions will be used to explore the relationship be-
tween potential disease modifying variables and disease
severity. In addition, for the 2 year follow-up data, linear
mixed models will be applied for analysis of differences
in disease progression. The primary outcome is a con-
tinuous variable, FSHD clinical severity score. The fixed
effect predictors are repeat length (divided in 1–3 D4Z4
repeat units (U), 4–6 U and 7–10 U), current age, her-
editary pattern and sex.
Time plan
Patients will be included in 2016 and follow-up visits
will be scheduled in 2018. The first results are expected
at the end of 2018.
Discussion
Results from the iFocus study will provide insights into
the clinical and genetic spectrum of children with FSHD.
These insights are vital for adequate symptomatic man-
agement and clinical trial-readiness. We propose exten-
sive qualitative and quantitative measurements specified
by age and use a modified format of the International
Classification of Functioning, Disability and Health cri-
teria. This structured approach enables us to give an
explorative, full-spectrum, unbiased clinical description
of FSHD in children.
Furthermore, this study aims to provide additional
insight in the epigenetic and environmental disease
modifying factors. This could help to unravel the aeti-
ology of FSHD and serve as a basis for prognostic and
therapeutic models.
One of the study’s strengths is the excellent recruit-
ment organisation in The Netherlands, thereby reducing
selection bias. There is a well-organized health system
with free access to paediatric neurology for every child.
In addition, our centers have a longstanding history of
excellent FSHD research and administration. Finally, all
participants can reach the study center within three
hours. These assets make it possible to execute a popu-
lation based, nation-wide study.
A critical issue is the small number of participants,
making it hard to verify correlations or differences in
subgroups, international collaborations are in prepar-
ation. Although, we expect to find differences in motor
functioning after 2 years of follow-up, this period will
possibly be too short for changes in other outcome mea-
sures such as wheelchair dependency. Therefore we aim
to continue the follow-up of this cohort for a longer
period of time.
In conclusion, the iFocus study is expected to yield
new knowledge on children with FSHD, aiming to
optimize clinical management, help unravelling the aeti-
ology of FSHD and serve as a basis for prognostic and
therapeutic studies.
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